GEN-MKT-18-7897-A
Sep 11, 2018 | Blogs, Forensic | 0 comments
Imagine being blindfolded, sent into a large (dark) room filled with obstacles and challenged to find an item, but you don’t know what that item is, and you have never seen it before. Then you must do the same again the next day, but you are looking for a different item, and it will be in a different place. The phrase fumbling around in the dark comes to mind!
Well, this is what it often feels like for forensic toxicologists trying to keep up with the unpredictable minefield of designer drugs — novel psychoactive substances (NPS).
NPS are synthetic chemicals, whether legal or illegal, closely related to known psychoactive compounds but with slightly altered composition. Not only does this make them difficult to recognize in routine screening, the fact that they are continually evolving – to evade regulation and defy law enforcement efforts — leaves drug screening labs in the dark on what compounds to target.
As if things aren’t tough enough, labs often receive wide varieties of sample types, ranging from blood and urine to hair and oral fluids, with complex biological components and challenging matrices. But it doesn’t stop there, some of these drugs are so potent that users only take a tiny amount, so the drug concentration is very low.
Fumbling around in the dark? Definitely! So, let’s remove the blindfold and shed some light on the matter.
Traditionally drug tests employ a range of targeted methods, and LC-MS/MS is recognized as one of the most efficient and reliable techniques available. The challenge is that these methods can only analyze known substances, limiting drug detection to compounds found on lists of pre-characterized analytes. In other words, if it’s not on the list, it won’t be seen.
How can toxicologists tackle the challenge of never-before-seen drugs? They need a screening tool that can detect trace amounts of unusual components in complex biological samples, even without any prior knowledge of their structural identities. This is the equivalent to removing the blindfold, turning the lights on, putting the obstacles aside and placing the item on a pedestal.
When our researchers here at SCIEX set out to do something, they don’t stop until they get there. As the opioid epidemic becomes the center of the drug overdose crisis, our team sought to develop a non-targeted screening workflow to screen novel fentanyl and its analogs in forensic biological samples.
Fill out the form on the right to download the technical note and learn more.
Trifluoroacetic acid (TFA) is emerging as one of the most concerning ultrashort-chain PFAS in Europe’s food supply – particularly in cereals, a staple consumed daily by millions. A report from PAN Europe reveals a widespread and largely unmonitored contamination trend that raises serious questions about food safety, regulatory blind spots, and future monitoring strategies.
PFAS analysis is complex, but expert guidance doesn’t have to be. In this episode of our ‘Ask the PFAS expert series’, we’re joined by Michael Scherer, Application Lead for Food and Environmental, to answer the most pressing questions in PFAS analysis. From why LC-MS/MS systems are the gold standard for analyzing diverse PFAS compounds, to which EU methods deliver reliable results for drinking water, and to practical steps to prevent contamination, Michael shares actionable insights to help laboratories achieve accuracy, consistency, and confidence in their workflows.
During an LC-MS/MS experiment, traditional fragmentation techniques like collision-induced dissociation (CID) have long been the gold standard. Electron-activated dissociation (EAD) is emerging as a transformative tool that enhances structural elucidation, particularly for complex or labile metabolites.
Posted by
You must be logged in to post a comment.
Share this post with your network